Correction for: CXCR4 knockdown enhances sensitivity of paclitaxel via the PI3K/Akt/mTOR pathway in ovarian carcinoma

por Zi, Dan, Li, Qing, Xu, Cheng-xiong, Zhou, Zhi-Wei, Song, Guan-Bin, Hu, Cheng-Bin, Wen, Fang, Yang, Han-Lin, Nie, Lei, Zhao, Xing, Tan, Jun, Zhou, Shu-Feng, He, Zhi-Xu
Publicado 2023

CXCR4 knockdown enhances sensitivity of paclitaxel via the PI3K/Akt/mTOR pathway in ovarian carcinoma

por Zi, Dan, Li, Qing, Xu, Cheng-xiong, Zhou, Zhi-Wei, Song, Guan-Bin, Hu, Cheng-Bin, Wen, Fang, Yang, Han-Lin, Nie, Lei, Zhao, Xing, Tan, Jun, Zhou, Shu-Feng, He, Zhi-Xu
Publicado 2022

Correction for: CXCR4 knockdown enhances sensitivity of paclitaxel via the PI3K/Akt/mTOR pathway in ovarian carcinoma

por Zi, Dan, Li, Qing, Xu, Cheng-xiong, Zhou, Zhi-Wei, Song, Guan-Bin, Hu, Cheng-Bin, Wen, Fang, Yang, Han-Lin, Nie, Lei, Zhao, Xing, Tan, Jun, Zhou, Shu-Feng, He, Zhi-Xu
Publicado 2022